[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336888-105":59,"doc-detail-336888-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-clinical-implications-of-rpl3-presence-in-brca-associated-cancers-unraveling-the-interplay-with-cancer-immunity","Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers - Unraveling the Interplay With Cancer Immunity","","Background: Few studies investigate the expression profile of RPL3 in breast cancer (BRCA). The study performs an in-depth analysis of RPL3 expression patterns in BRCA, emphasizing relevance to therapy prediction and prognosis. Methods: RPL3 is elevated in malignant cells, with expression linked to tumor size and overall survival. RPL3-associated terms and pathways are identified, and correlations with breast carcinoma immunity are assessed across immune cell lines. The study also evaluates RPL3 versus tumor mutational burden (TMB) in BRCA and examines links between RPL3 expression and chemotherapy drug sensitivity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-clinical-implications-of-rpl3-presence-in-brca-associated-cancers-unraveling-the-interplay-with-cancer-immunity/336888/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-clinical-implications-of-rpl3-presence-in-brca-associated-cancers-unraveling-the-interplay-with-cancer-immunity/336888.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How is RPL3 expression related to clinical outcomes in BRCA?","Question",{"text":112,"@type":113},"RPL3 is notably elevated in malignant cells, and higher expression is closely associated with tumor size and overall survival outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the relationship between RPL3 expression and cancer immunity?",{"text":117,"@type":113},"The findings show a strong correlation between RPL3 expression and breast carcinoma immunity, including differing expression levels across various immune cell lines, suggesting a role in immune infiltration.",{"name":119,"@type":110,"acceptedAnswer":120},"How does RPL3 relate to treatment response and tumor mutational burden in BRCA?",{"text":121,"@type":113},"The study examines the association between RPL3 expression and tumor mutational burden (TMB), and evaluates how RPL3 expression levels correlate with drug sensitivity to BRCA chemotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336888,1790163679,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers: Unraveling the Interplay With Cancer Immunity  \nLinyi Wang1*, Minlong Chen1*, Zhaosheng Ma1*, Hanqian Zeng1, Bojian Xie1 and Shiwen Xu2  \n1Department of Surgical Oncology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China . 2 Department of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China .  \nClinical Medicine Insights: Oncology  \nVolume 18: 1–10  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/11795549241285387](DOI: 10.1177/11795549241285387)  \n|  |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>BACkgRoUnd: Few studies have explored the expression profile of RPL3 in breast cancer (BRCA) . Our research provided an in-depth analysis of RPL3 expression patterns in BRCA, highlighting its significance for therapy prediction and prognosis .\u003Cbr>METhodS: RPL3 was notably elevated in malignant cells, and its expression level was closely associated with tumor size and overall survival outcomes . Our study also identified RPL3-related terms and pathways and revealed a strong correlation between RPL3 expression and breast carcinoma immunity, demonstrating inconsistent expression levels in various immune cell lines . In addition, we examined the relationship between RPL3 expression and tumor mutational burden (TMB) in BRCA . To assess the clinical implications of BRCA chemotherapy, we investigated the correlation between RPL3 expression levels and drug sensitivity.\u003Cbr>RESULTS: Our findings suggest that RPL3 plays a critical role in the BRCA process and is associated with immune infiltration, indicating its potential as a novel immunotherapy target in BRCA treatment.\u003Cbr>ConCLUSIonS: In summary, our research underscores the importance of RPL3 expression levels in tumorigenesis and its potential for guiding BRCA immunotherapy.\u003Cbr>kEyWoRdS: RPL3, breast cancer, immune therapy, immune infiltration, tumor |  |\n| RECEIVEd: March 22, 2024. ACCEPTEd: September 3, 2024.\u003Cbr>TyPE: Original Research Article | CoRRESPondIng AUThoRS: Bojian Xie, Department of Surgical Oncology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai 317000,\u003Cbr>Zhejiang, China. Email: [bojianxie1@hotmail.com](bojianxie1@hotmail.com) |\n| FUndIng: The author(s) received no financial support for the research, authorship, and/or publication of this article.\u003Cbr>dECLARATIon oF ConFLICTIng InTERESTS: The author(s) declared no potential\u003Cbr>conflicts of interest with respect to the research, authorship, and/or publication of this article. | Shiwen Xu, Department of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai 317000, Zhejiang, China.\u003Cbr>Email: [shiwenxu_onco@hotmail.com](shiwenxu_onco@hotmail.com) |\n| Introduction | key components of protein synthesis, RPs not only regulate |\n| The BRCA has surpassed lung carcinoma as the most common | transcriptional and translational processes but also participate |\n| cause of cancer and the fifth cause of death globally.1 There are | in various biological mechanisms.4 The RPL3, a subset of RPs, |\n| various therapies used in BRCA management, including sur- | is confirmed to show a substantial part in cancer progress and |\n| gery, chemotherapy, radiotherapy, targeted therapy, and immu- | chemotherapy sensitivity.5,6 Earlier reports have discovered |\n| notherapy.2,3 Nevertheless, tumor management is not always | that both hematopoietic and non-hematopoietic carcinoma |\n| adequate. Approximately 2.3 million patients were newly diag- | cell lines with increased RPL3 expression reveal greater sensi- |\n| nosed, and nearly 68 000 died with these therapies in 2020. | tivity to drugs,5 whereas the loss of RPL3 creates chemother- |\n| The 5-year survival rate in metastatic BRCA ","cbCaijtODsOu0OO4","https://ap.wps.com/l/cbCaijtODsOu0OO4","pdf",7161755,"English","# Abstract\n## Methods and Results\n## Conclusion\n# Introduction","[{\"question\":\"How is RPL3 expression related to clinical outcomes in BRCA?\",\"answer\":\"RPL3 is notably elevated in malignant cells, and higher expression is closely associated with tumor size and overall survival outcomes.\"},{\"question\":\"What is the relationship between RPL3 expression and cancer immunity?\",\"answer\":\"The findings show a strong correlation between RPL3 expression and breast carcinoma immunity, including differing expression levels across various immune cell lines, suggesting a role in immune infiltration.\"},{\"question\":\"How does RPL3 relate to treatment response and tumor mutational burden in BRCA?\",\"answer\":\"The study examines the association between RPL3 expression and tumor mutational burden (TMB), and evaluates how RPL3 expression levels correlate with drug sensitivity to BRCA chemotherapy.\"}]","Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers - Unraveling the Interplay With Cancer Immunity | PDF",1790016964,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85bbe3eaba5786584863e30fb181b972.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7c8feed1ad1b324f294ca2db9812008.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42dc2ddf115e93d8f018419e1a6976f2.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db16e20995c7098ce2293d99b98baa54.webp",980,1385]